Captor Therapeutics Spolka Akcyjna (WSE:CTX)
Poland flag Poland · Delayed Price · Currency is PLN
73.00
-0.40 (-0.54%)
At close: Dec 5, 2025

WSE:CTX Income Statement

Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
7.5715.8313.29.163.99-
Revenue Growth (YoY)
-60.89%19.88%44.15%129.75%--
Cost of Revenue
2.635.236.32.090.74-
Gross Profit
4.9510.66.97.073.25-
Selling, General & Admin
11.7111.4616.1424.0730.689.89
Research & Development
45.1243.970.8944.1623.1223.57
Other Operating Expenses
-9.83-5.79-7.11-22.79-17.71-21.24
Operating Expenses
47.0149.5679.9245.4436.0912.22
Operating Income
-42.06-38.97-73.02-38.36-32.84-12.22
Interest Expense
-0.32-0.39-0.27-0.32-0.4-0.39
Interest & Investment Income
1.681.043.083.13--
Currency Exchange Gain (Loss)
-0.01-0.07-0.27-0.08-0.06-0.09
Other Non Operating Income (Expenses)
-0-0.05-0.05-0.26-0.41-
EBT Excluding Unusual Items
-40.71-38.43-70.53-35.89-33.7-12.69
Asset Writedown
----1.13-
Pretax Income
-40.71-38.43-70.53-35.89-32.57-12.69
Income Tax Expense
--0.06---
Net Income
-40.71-38.43-70.58-35.89-32.57-12.69
Net Income to Common
-40.71-38.43-70.58-35.89-32.57-12.69
Shares Outstanding (Basic)
555444
Shares Outstanding (Diluted)
555444
Shares Change (YoY)
6.24%0.30%11.46%0.97%14.99%-
EPS (Basic)
-7.68-8.25-15.19-8.61-7.89-3.54
EPS (Diluted)
-7.69-8.25-15.19-8.61-7.89-3.54
Free Cash Flow
-7.8-32.3-55.21-23.84-33.59-0.81
Free Cash Flow Per Share
-1.47-6.93-11.88-5.72-8.14-0.23
Gross Margin
65.32%66.95%52.28%77.21%81.41%-
Operating Margin
-555.61%-246.24%-553.11%-418.91%-823.88%-
Profit Margin
-537.79%-242.82%-534.69%-391.94%-817.16%-
Free Cash Flow Margin
-103.04%-204.12%-418.22%-260.32%-842.60%-
EBITDA
-37.4-33.91-67.58-31.27-25.49-5.61
EBITDA Margin
--214.27%----
D&A For EBITDA
4.665.065.447.097.366.6
EBIT
-42.06-38.97-73.02-38.36-32.84-12.22
EBIT Margin
--246.24%----
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.